AzurRx BioPharma Inc (AZRX)

Overview

AzurRx BioPharma, Inc. is a company focused on the research and development of non-systemic biologics to address the medical needs of patients with gastrointestinal (GI) disorders. Based in Brooklyn, New York, the company employs 12 full-time professionals who are dedicated to innovating treatment options for GI diseases. The firm's primary aim is to develop therapeutic proteins that improve the quality of life for patients suffering from various GI conditions, including those stemming from chronic pancreatitis (CP) and cystic fibrosis (CF), as well as conditions caused by hospital-acquired infections and antibiotic-associated diarrhea.

Products and Services

• MS1819

MS1819 stands as a pivotal product in AzurRx BioPharma’s portfolio, developed as a recombinant deoxyribonucleic acid (DNA) technology-based therapeutic protein. Originating from Yarrowia lipolytica, known as LIP2, this acid-resistant secreted lipase aims to treat exocrine pancreatic insufficiency (EPI), a condition often associated with chronic pancreatitis (CP) and cystic fibrosis (CF). MS1819's innovative approach, focusing on enhancing the digestion of fats and the absorption of fat-soluble vitamins and nutrients, provides hope for significantly improving the lives of those afflicted with EPI.

• AZX1101

AZX1101 represents an adventurous venture into combating nosocomial infections, specifically targeting the prevention of infections caused by antibiotic-resistant bacterial strains and the avoidance of antibiotic-associated diarrhea (AAD). This recombinant β-lactamase enzyme combination is derived from bacterial origins. It serves as a protective measure against the adverse effects of parenteral administration of β-lactam antibiotics commonly used in hospital settings. By deactivating the antibiotics within the gastrointestinal tract, AZX1101 has the potential substantially to lower the risk of both nosocomial infections and AAD, offering a proactive solution to a growing public health concern.